Poolbeg Pharma to present at investor conferences

Poolbeg Pharma
[shareaholic app="share_buttons" id_name="post_below_content"]

Poolbeg Pharma plc (LON:POLB), a clinical stage infectious disease pharmaceutical company with a capital light clinical model, today announced that members of its management team will be attending four upcoming investor events across September and October.

· Proactive Investors One2One Forum (virtual) on 16 Sep 2021. Registration Link: click here

· Small Company Champion Investor Presentation on 17 Sep 2021 at The Menphys Hub, Bassett Street South, Wigston, Leicester LE18 4PE. Registration Link: click here

· Shares Magazine Investor Webinar (virtual) on 5 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

· London South East Webinar (virtual) on 19 Oct 2021. Registration link will be available on the Poolbeg Pharma website: click here

The above event details may be subject to change. Further information and any updates will be on the events section of the Poolbeg Pharma website.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma , said:

“Following continuing demand after an oversubscribed AIM listing in July and a share price above the IPO price, I am looking forward to sharing how our capital light model and a scalable platform for growth will deliver value creation for our shareholders. Poolbeg Pharma is targeting a rapidly expanding market of infectious diseases, which is expected to exceed $250B by 2025. These events will be an opportunity to discuss our attractive, Phase II ready lead asset (POLB 001) tackling the inflammatory response to severe influenza, and our special access to a unique data bank of 20 years of infectious disease data in humans which we will mine to identify new, compelling therapeutics.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
Poolbeg Pharma secures US patent approval for POLB 001, enhancing its IP portfolio and advancing treatments for severe influenza and cytokine storms.
Poolbeg Pharma to showcase POLB 001's promising results in reducing CRS at ASH 2024, highlighting breakthroughs in cancer immunotherapy safety.
Discover six high-growth AIM-listed British companies delivering exceptional returns, with share prices surging up to 150% in the past year.
Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF) has updated its registered address to 40 Bank Street, Floor 24, London, E14 5NR, United Kingdom.

Search

Search